Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
Kelley C. O’donnell, Brian T Anderson, Frederick S. Barrett, Michael P. Bogenschutz, Charles S. Grob, Peter S. Hendricks, Benjamin Kelmendi, Sandeep M. Nayak, Christopher R. Nicholas, Casey Paleos, Christopher S. Stauffer, Natalie Gukasyan
Am J Psychiatry 2024 DOI: 10.1176/appi.ajp.20230661 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Critical response or commentary Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy Psilocybin |
| Keywords | Psilocybin therapy Psilocybin-assisted therapy Mushroom therapy Mental healthcare Psychiatric treatment Psychological therapy Psychedelic medicine Entheogenic medicine Hallucinogen therapy Treatment efficacy Therapy effectiveness Positive outcomes Therapeutic benefits Safety profile Treatment safety Risk assessment Tolerability |
| Citations | 31 |
| Key points | Argues that Goodwin and colleagues' commentary on psilocybin-assisted therapy contains significant misinterpretations and omissions that could hinder scientific discourse. |
Abstract
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.